8-K current report · filed Oct 27, 2026

Cardiff Oncology, Inc. (CRDF) 8-K Current Report: October 27, 2026

Item 5.02Item 5.03Item EX-99.1Item 7.01CRDF overview

Short answer

Cardiff Oncology, Inc. (CRDF) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Chief Medical Officer Roger Sidhu departed October 22, 2026 through a mutually agreed transition.

Cardiff Oncology, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Chief Medical Officer Roger Sidhu departed October 22, 2026 through a mutually agreed transition
  • Leila Alland appointed interim Chief Medical Officer effective October 23, 2026
  • Interim appointment runs through April 22, 2027 unless services conclude earlier
  • Consulting fee $35,000 monthly, with up to 50% professional time dedicated to Cardiff
  • Leadership change places clinical development oversight with an oncology executive experienced across multiple biotech companies

Item 5.03 · Amendments to Articles of Incorporation or Bylaws

  • Authorized common shares increased to 300,000,000, expanding potential equity issuance capacity
  • Effective October 22, 2026 upon Delaware filing
  • Greater authorization supports financing flexibility but creates potential shareholder dilution risk

Item 7.01 · Regulation FD Disclosure

  • Dr. Sidhu resigned as Chief Medical Officer, creating a senior clinical leadership transition
  • Dr. Alland appointed interim Chief Medical Officer, providing temporary oversight of clinical development
  • Leadership change potentially relevant to CRDF’s trial execution, regulatory strategy and investor confidence

Item EX-99.1 · Exhibit EX-99.1

  • Leila Alland, MD appointed interim Chief Medical Officer, replacing Roger Sidhu
  • Leadership change arrives before planned Phase 3 launch in first quarter 2027
  • Phase 2 colorectal cancer trial ongoing, with median PFS not reached in proposed Phase 3 regimen
  • Remaining trial patients have received treatment for more than 18 months, supporting continued clinical focus on durability
  • Appointment adds oncology development expertise but creates interim leadership uncertainty ahead of registration-enabling execution

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Cardiff Oncology, Inc. 8-K filings

Get the next CRDF 8-K as it lands

Follow CRDF for push alerts, or ask the research agent what this filing means.